Letrozole High Dose (10 mg) Compared to Letrozole Low Dose( 5 mg) for Ovarian Stimulation in Infertile Women With Polycystic Ovary Syndrome
Key facts
- Who runs it
- Mst.Sumyara Khatun
- Where
- Bangladesh1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 86 people enrolled
- Started
- 1 Feb 2025
- Ended
- 1 Feb 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tab.Letrozole 10 mg for 5 days
- Tab.Letrozole 5mg for 5 days
- Record updated
- 12 August 2026
Who can take part
- Age
- 18 years to 35 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age: 18-35 years old
- BMI : 18-30 kg/m2
- Diagnosed cases of PCOS patients according to Rotterdam criteria
- Corrected hypothyroidism and hyperprolactinemia
Who cannot take part
- History of hypersensitivity to letrozole; -; -
- Women with other infertility factors (endometriosis, tubal and uterine causes of infertility)
- Male factor infertility
- Impaired hepatic or renal function
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if drug letrozole 10mg for 5 days works better than letrozole 5mg for 5 days for ovarian stimulation in infertile women with PCOS. It will also learn about the safety of drug letrozole . The main questions it aims to answer are:
Read full original descriptionShow less
What medical problems do participants have when taking drug letrozole? Researchers will compare drug letrozole 10mg for 5 days works better than letrozole 5 mg for 5 days for ovarian stimulation in infertile women with PCOS
Participants will:
The experimental arm (p1) will be treated with letrozole 10 mg for 5 days. The comparator arm (p2) will receive letrozole 5 mg for 5 days for ovulation induction for consecutive 3 months Treatment will start from the 2nd day of menstruation cycle or withdrawal bleeding after the baseline visit and investigations.
Ovarian response will be assessed by trans-vaginal monitoring of follicle growth around day 10 of menstrual cycle
The 2 groups in the trial
- Tab.Letrozole 10 mg for 5 daysTreatment being tested
Tab letrozole 10 mg for 5 days from day 2-3 of menstruation/withdrawal bleeding (5mg at morning and 5mg bed time for 5 days) for 3 cycle
- Tab.Letrozole 5 mg for 5 daysExisting treatment, for comparison
Tab letrozole 5mg for 5 days from day 2-3 of enstruation/withdrawal bleeding ( 5mg at bed time for 5 days) for three cycle
Treatment: Tab.Letrozole 5mg for 5 days
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 12 August 2026